Barclays
ALZN icon

Barclays’s Alzamend Neuro ALZN Stock Holding History

Barclays’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-486
Closed -$4.15K – 5238
2025
Q1 		$4.15K Buy
+486
New +$4.45K ﹤0.01% 4948

Other funds holding ALZN

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

Barclays's ALZN Position: Q2 2025 in Review

Barclays sold out of Alzamend Neuro (ALZN) in Q2 2025, closing a stake of 486 shares — an estimated $4.15K sold.

Barclays first reported a position in ALZN in Q1 2025 and held it in 1 quarter. The position peaked at $4.15K in Q1 2025. 7 funds tracked by Wall St. Rank hold ALZN as of Q2 2025.

  • Barclays reported no remaining Alzamend Neuro position as of Q2 2025 after selling out during the quarter.
  • Barclays sold 486 Alzamend Neuro shares in Q2 2025, an estimated $4.15K.
  • Barclays first reported a position in Alzamend Neuro in Q1 2025 and held it in 1 quarter.
  • Barclays's Alzamend Neuro position peaked at $4.15K in Q1 2025.
  • 7 funds tracked by Wall St. Rank held Alzamend Neuro as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.